SCHEMBL336184

SCHEMBL336184

CCOC(=O)c1cnc(C(F)(F)F)nc1NC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 10/20 0.69
JUN P05412 9/20 0.69
NFKB2 Q00653 9/20 0.69
RELA Q04206 9/20 0.69
FOS P01100 8/20 0.69
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 2/20 0.54
NPC1 O15118 1/20 0.54
MAPT P10636 1/20 0.54
HPGD P15428 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SYK P43405 1/20 0.42
HSP90AA1 P07900 1/20 0.42
ATF1 P18846 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8394502 0.88 JUN (0.67) NFKB1JUNNFKB2RELAFOS
SCHEMBL15639703 0.87 JUN (0.66) NFKB1JUNNFKB2RELAFOS
SCHEMBL17363161 0.86 JUN (0.65) NFKB1JUNNFKB2RELAFOS
SCHEMBL17363146 0.85 JUN (0.64) NFKB1JUNNFKB2RELAFOS
SCHEMBL17363186 0.84 JUN (0.62) NFKB1JUNNFKB2RELAFOS
SCHEMBL423492 0.83 JUN (0.60) NFKB1JUNNFKB2RELAFOS
SCHEMBL15170547 0.82 NFKB1 (0.60) NFKB1JUNNFKB2RELAFOS
SCHEMBL8543216 0.82 KDM4E (0.72) NFKB1JUNNFKB2RELAFOS
SCHEMBL4425453 0.82 JUN (0.59) NFKB1JUNNFKB2RELAFOS
SCHEMBL15624862 0.81 ALDH1A1 (0.60) NFKB1JUNNFKB2RELAFOS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 EP disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN NFKB1 528/4885JUN 1723/4885NFKB2 492/4885
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase EGLN3, HIF1AN, EGLN2 NFKB1 591/4885JUN 1311/4885NFKB2 706/4885
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE HIF1AN, EGLN3, EGLN2 NFKB1 550/4885JUN 1667/4885NFKB2 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.